Professional article
English

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

Published in

Annals of the rheumatic diseases, vol. 72, no. 11, p. 1786-1792

Publication date

2013

Abstract

Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares.

Keywords

  • Adult
  • Antirheumatic Agents/administration & dosage/blood
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Monitoring/methods
  • Female
  • France
  • Humans
  • Hydroxychloroquine/administration & dosage/blood
  • Lupus Erythematosus, Systemic/drug therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome

UNIGE affiliation entities

Not a UNIGE publication

Citation (ISO format)

COSTEDOAT-CHALUMEAU, Nathalie et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). In: Annals of the rheumatic diseases, 2013, vol. 72, n° 11, p. 1786–1792. doi: 10.1136/annrheumdis-2012-202322

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0003-4967
574views
0downloads

Technical informations

Creation

07/11/2015 14:57:00

First validation

07/11/2015 14:57:00

Update

14/03/2023 23:57:15

Status update

14/03/2023 23:57:14

Last indexation

31/10/2024 02:14:21
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated